公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2014 | Association of dysmenorrhea with interstitial cystitis/bladder pain syndrome: A case-control study | Chung S.-D.; SHIH-PING LIU ; Lin H.-C.; Kang J.-H. | Acta Obstetricia et Gynecologica Scandinavica | 12 | 12 | |
2018 | Chronic pulmonary exposure to traffic-related fine particulate matter causes brain impairment in adult rats 11 Medical and Health Sciences 1109 Neurosciences | Shih C.-H.; Chen J.-K.; Kuo L.-W.; Cho K.-H.; Hsiao T.-C.; Lin Z.-W.; Lin Y.-S.; Kang J.-H.; Lo Y.-C.; Chuang K.-J.; TSUN-JEN CHENG ; TA-CHIH HSIAO et al. | Particle and Fibre Toxicology | 41 | 39 | |
2011 | Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach | Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH ; Thongprasert S.; Lu S.; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 35 | 36 | |
2020 | Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan | Kang J.-H.; YEN-LING LAI ; WEN-FANG CHENG ; Kim H.-S.; KUAN-TING KUO ; YU-LI CHEN ; Lee Y.-Y. | Scientific Reports | 8 | 7 | |
2016 | East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL) | Park K.; Kim J.-H.; Cho E.K.; Kang J.-H.; JIN-YUAN SHIH ; Zimmermann A.H.; Lee P.; Alexandris E.; Puri T.; Orlando M. | Cancer Research and Treatment | 19 | 15 | |
2018 | Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants from Asian Countries | Garland S.M.; Pitisuttithum P.; Ngan H.Y.S.; Cho C.-H.; Lee C.-Y.; CHI-AN CHEN ; Yang Y.C.; Chu T.-Y.; Twu N.-F.; Samakoses R.; Takeuchi Y.; Cheung T.H.; Kim S.C.; LI-MIN HUANG ; Kim B.-G.; Kim Y.-T.; Kim K.-H.; Song Y.-S.; Lalwani S.; Kang J.-H.; Sakamoto M.; Ryu H.-S.; Bhatla N.; Yoshikawa H.; Ellison M.C.; Han S.R.; Moeller E.; Murata S.; Ritter M.; Sawata M.; Shields C.; Walia A.; Perez G.; Luxembourg A. | Journal of Infectious Diseases | 30 | 23 | |
2020 | Enhancing community participation for stroke survivors with cognitive impairment: Study protocol for a randomised controlled trial in Taiwan | Chang F.-H.; Chiu V.; Ni P.; Lin Y.-N.; Kang J.-H.; Liou T.-H.; LU LU ; DER-SHENG HAN ; Skidmore E.R. | BMJ Open | 3 | 2 | |
2016 | First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study | Park K.; CHONG-JEN YU ; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. | JAMA Oncology | 200 | 164 | |
2014 | Herpes zoster is associated with prior statin use: A population-based case-control study | Chung S.-D.; Tsai M.-C.; SHIH-PING LIU ; Lin H.-C.; Kang J.-H. | PLoS ONE | 13 | 12 | |
2010 | Hypothyroidism and the risk of developing open-angle glaucoma: A five-year population-based follow-up study | Lin H.-C.; Kang J.-H.; YI-DER JIANG ; Ho J.-D. | Ophthalmology | 24 | 20 | |
2021 | Mechanical properties of compact bone defined by the stress-strain curve measured using uniaxial tensile test: A concise review and practical guide | Lin C.-Y; Kang J.-H.; CHE-YU LIN | Materials | | | |
2021 | Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | Park K.; Jӓnne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU ; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. | Cancer | 17 | 10 | |
2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 397 | 341 | |
2017 | A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141 | Kiyota N.; Hasegawa Y.; Takahashi S.; Yokota T.; Yen C.-J.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Sum Kenneth Li W.; Ferris R.L.; Gillison M.; Namba Y.; Monga M.; Lynch M.; Tahara M. | Oral Oncology | 80 | 69 | |
2020 | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | Yen C.-J.; Kiyota N.; Hanai N.; Takahashi S.; Yokota T.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Li W.S.K.; Ferris R.L.; Gillison M.; Endo T.; Jayaprakash V.; Tahara M. | Head and Neck | 25 | 19 | |